This report contains market size and forecasts of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics in Global, including the following market information:
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics include Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals, Sun Pharma, Hutchison China MediTech Limited, Exelixis, Inc. and Tarveda Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Segment Percentages, by Type, 2021 (%)
Chemotherapy
Peptide-Receptor Radionuclide Therapy
Others
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gastroenteropancreatic Neuroendocrine Tumor Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Gastroenteropancreatic Neuroendocrine Tumor Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis, Inc.
Tarveda Therapeutics